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ABSTRACT
The Nm23 metastasis suppressor family is involved in physiological and 
pathological processes including tumorigenesis and metastasis. Although the inverse 
correlation of Nm23 level with tumor metastasis potential has been widely observed, 
the mechanisms that regulate the expression of Nm23 remain poorly understood. Our 
previous studies have revealed that Nm23-H1/2 isoforms are upregulated by RGS19, 
a regulator of G protein signaling (RGS) protein which accelerates the termination 
of Gi signals. Here, we examined the ability of RGS19 to stimulate transcriptional 
regulation of Nm23 by screening a panel of luciferase reporter genes. Transient 
and stable overexpression of RGS19 upregulated the Nm23-H1/2 protein levels and 
activated several transcription factors including CREB, AP-1 and SRE in HEK293 cells. 
Interestingly, agents that increase the intracellular cAMP level and the phosphorylation 
of CREB (e.g., adrenergic receptor agonist, forskolin, and cAMP analogues) upregulated 
the expression of Nm23-H1/2 in HEK293 cells and several cancer cell lines including 
A549, HeLa, MDA-MB-231, and MDA-MB-435s cells. Conversely, inhibition of protein 
kinase A (PKA) by H-89 suppressed the phosphorylation of CREB and reduced the 
expression of Nm23-H1/2. Furthermore, activation of PKA attenuated cancer cell 
migration in wound healing and transwell assays. Collectively, these results revealed 
a PKA-dependent mechanism for controlling Nm23-H1/2 expression.
INTRODUCTION
Metastasis suppressor genes, which exhibit a reduced 
expression in metastatic tumor cells, are defined by their 
ability to inhibit metastatic dissemination without impairing 
primary tumor growth [1]. The prototypical metastasis 
suppressor is Nm23 which has the ability to down-regulate 
metastasis formation independently of primary tumor size 
[2]. The ten members of the Nm23 family are involved 
in diverse physiological and pathological processes, 
ranging from proliferation, differentiation, development, 
ciliary functions to metastasis. Among them, the two 
most abundantly expressed isoforms are Nm23-H1 and 
Nm23-H2 [3]. In human cohort studies, low Nm23-H1 
expression is correlated with high metastatic potential in 
a subset of melanoma, liver, colon, and breast cancers [4]. 
Its role as a metastasis suppressor is strongly indicated 
by loss of expression at the early stages of the metastatic 
cascade [5], and the ability to reduce metastasis in a variety 
of cancer cell models [2, 6].
Given the strong inverse correlation between cancer 
metastasis and the expression level of Nm23-H1/2, an 
ability to manipulate the expression of Nm23 proteins may 
have profound impact on curbing metastasis. However, 
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little is known with regard to the regulatory mechanisms 
that control the expression of Nm23. Small molecules 
such as all-trans retinoic acid, medroxyprogesterone 
acetate (MPA), and a variant of vitamin D have been 
reported to upregulate the expression of Nm23 in various 
cell types, while thyroid hormone has been shown to 
downregulate Nm23 [7–10]. Furthermore, inhibition of 
DNA methylation apparently participates in the elevation 
of Nm23-H1 expression [11]. Analysis of the promoter 
regions of NME1 and NME2 (encoding for Nm23-H1 and 
H2, respectively) have revealed binding sites for several 
known transcription factors including AP-1, Oct-2 (NME1) 
and PuF (NME2) [12, 13]. Using molecular analysis of the 
Nm23-H1 promoter with sequential deletions, a 248 bp 
fragment of the promoter containing a MAF/Ets site and a 
CTF/NF1 half site was implicated in elevating Nm23-H1 
expression [11]. As for Nm23-H2, most of the studies on 
its transcriptional regulation were focused on the Myc 
binding sites in its promoter region [14]. More recently, 
we have demonstrated that Nm23-H1/2 can be upregulated 
by RGS19, a member of the regulators of G protein 
signaling (RGS proteins), although no clear mechanism 
was immediately discernable [15].
The ability of RGS19 to upregulate Nm23-H1/2 is 
rather intriguing. G protein-coupled receptors (GPCRs) 
have long been recognized as potential oncogenes and tumor 
suppressors by regulating G protein signaling networks that 
modulate cell proliferation, and drugs targeting GPCRs have 
been utilized in cancer therapy [16]. Rapid termination of 
G protein signals by RGS proteins can potentially modulate 
growth signals and hence tumorigenesis. Multiple RGS 
proteins are known to be differentially expressed between 
normal and cancerous tissues in a variety of cancers, 
including ovarian cancer and melanoma [17]. Interestingly, 
RGS19 appears to suppress tumorigenesis via upregulating 
Nm23-H1/2 [15, 18]. The enhanced expression of 
Nm23-H1/2 leads to the phosphorylation and translocation 
of a scaffolding protein, kinase suppressor of Ras (KSR), 
which is required for efficient propagation of growth signals 
along the Ras/Raf/MEK/ERK axis [15]. Since RGS proteins 
are not generally known to modulate the expression of 
other proteins, the upregulation of Nm23-H1/2 by RGS19 
provides an invaluable opportunity to examine whether 
RGS proteins can indirectly regulate transcription. In this 
study we present evidence that activation of the cAMP/
PKA/CREB pathway can lead to increased expression of 
Nm23-H1/2, which may provide a new approach to control 
the process of cancer metastasis.
RESULTS
RGS19 activates several transcription factors 
with putative binding sites on the promoter 
regions of NME1/2
Since we have previously shown that the transcript 
levels of Nm23-H1/2 variants are significantly elevated 
in HEK293 cells stably expressing RGS19 (henceforth 
referred to as 293/RGS19) [15], it seems likely that RGS19 
can stimulate the transcription of Nm23-H1/2. The promoter 
region of NME1 is around 2.1 kb and that of NME2 is less 
than 4 kb [11, 14, 19]. Early studies have identified a number 
of binding sites for transcription factors in the promoter 
regions of NME1 and NME2 [11-13, 20]. Using the matrix-
based MatInspector analysis, a number of transcription 
factor binding sites were found in the promoter regions 
of NME1 and NME2. In order to focus on the putative 
transcriptional activity specifically driven by RGS19, 
several transcription factors were selected on the basis of 
their potential regulation by G protein signals and possible 
interaction with Nm23-H1/2 (Table 1). As an RGS protein, 
RGS19 serves as a GAP (GTPase-activating protein) 
for Gα
i/o
, Gα
q
, Gαt, and Gαz with differential inhibitory 
potentials [21]. Transcription factors such as NFκB [22, 
23], NFAT [24], and STAT3 [25] are known to be regulated 
by Gi-coupled receptors. CREB, AP-1 and SRF were also 
selected in view of their linkage to Gαs and Gαq signals [26]. 
All of the selected transcription factors are predicted to bind 
to the promoter regions of NME1/2 at multiple sites (Table 
1) and their relative locations with respect to the translation 
initiation site (TIS) are depicted in Figure 1A.
Prior to testing the activity of transcription factors 
by means of reporter gene assays, we first confirmed that 
293/RGS19 cells have elevated levels of Nm23-H1/2. As 
shown in Figure 1B, the expression of Nm23-H1 (23 kDa) 
and Nm23-H2 (17 kDa) in 293/RGS19 cells was indeed 
significantly higher (~3-fold) than those of HEK293 cells. 
Similarly, transient expression of RGS19 in HeLa cells 
also led to a higher expression level of Nm23-H1/2 as 
compared to that of the vector control (Figure 1C). These 
results confirmed our earlier findings [15] and indicated 
that upregulation of Nm23-H1/2 by RGS19 may occur in 
different cell types. To test the potential involvement of 
the selected transcription factors, we transiently expressed 
different luciferase reporter genes with or without RGS19 
in HEK293 cells. Increasing amounts of luciferase reporter 
genes were used in the transfections to ensure that the 
reporter constructs would not become limiting. It was 
also confirmed that different DNA amounts of luciferase 
(luc) reporter gene did not affect the expression level of 
RGS19 (Supplementary Figure 1). The luciferase activities 
driven by AP-1, CRE, SRE or STAT3 were significantly 
stimulated in RGS19 co-expressing cells as compared to 
that of the vector controls (Figure 1D); the activities of 
pCRE-luc and pSTAT3-luc were weaker than those of the 
other two reporters. In contrast, neither NFκB nor NFAT 
driven luciferase activity was stimulated in RGS19 co-
expressing cells.
AP-1, CRE and SRE transcription factors are 
activated in 293/RGS19 cells
The preceding experiments suggest that AP-1, CRE, 
SRE, and STAT3 transcription factors might be stimulated 
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by RGS19. If this is indeed true, then 293/RGS19 cells 
should exhibit elevated luciferase activities when the 
corresponding reporter genes are introduced. Hence, 
the different reporter genes were transiently transfected 
into HEK293 or 293/RGS19 cells and the basal as well 
as stimulated luciferase activities were determined. 
Basal (control) AP-1, CRE, and SRE driven luciferase 
activities were significantly higher in 293/RGS19 cells 
than the parental HEK293 cells (Figure 2). Although 
basal AP-1 and SRE activities in 293/RGS19 cells were 
only elevated by less than threefold, basal CRE activity 
was robustly increased by several hundredfold (Figure 2). 
Known activators of these reporter genes also exhibited 
similar levels of stimulation, with phorbol 12-myristate 
13-acetate (PMA) and FBS weakly stimulated AP-1 and 
SRE reporters in HEK293 cells, while forskolin strongly 
activated the CRE reporter (Figure 2). On the other hand, 
the STAT3-dependent luciferase activity in 293/RGS19 
cells was no different than that of HEK293 cells (Figure 
2). Nevertheless, STAT3 luciferase activity was effectively 
stimulated by IL-6, indicating that the reporter gene was 
fully functional in the transfectants. In each case, the 
expression of RGS19 in 293/RGS19 cells was unaffected 
by the drug treatments (Figure 2). Intriguingly, the 
magnitude of CREB activation in the 293/RGS19 stable 
line was much higher than that of transient overexpression 
of RGS19 (Figures 1D and 2). One possible explanation 
is that transient transfections do not allow sufficient time 
to accumulate activated CREB, whereas the relatively 
long selection time required for establishing stable 
293/RGS19 cells would have ensured the buildup of 
phosphorylated CREB for efficient stimulation of the 
pCRE-luc reporter gene.
Activation of PKA pathway upregulates the 
expression of Nm23-H1/2
Since CRE sites are predicted to be present in the 
promoter regions of NME1 and NME2 (Figure 1A) and 
basal CRE activity was significantly increased in RGS19 
transient transfectants (Figure 1D) and 293/RGS19 
cells (Figure 2), it seems plausible that Nm23-H1/2 
expression can be regulated by the cAMP/PKA pathway 
which lies upstream of the CREB transcription factor. 
To test this possibility, we employed several approaches 
to manipulate the production of intracellular cAMP and 
the function of its canonical target. We first asked if 
forskolin, a potent direct activator of adenylyl cyclase 
(AC), can upregulate the protein level of Nm23-H1/2 
in HEK293 cells. HEK293 cells were treated with 
increasing concentrations of forskolin (0.5 to 50 μM) 
for 24 h and then lysed for the immunodetection of 
Nm23-H1/2 and CREB phosphorylation by specific 
antisera. Expression of Nm23-H1/2 was significantly 
increased in HEK293 cells treated with 1 μM forskolin 
for 24 h (Figure 3A). Although increased expression of 
Nm23-H1/2 was also detected in some experiments at 
5 μM forskolin, higher concentrations failed to elevate 
Nm23-H1/2 expression. Forskolin also increased the 
level of phosphorylated CREB at Ser133 without affecting 
the total CREB (Figure 3A).
Similarly, isoproterenol (ISO), an agonist of 
β2-adrenergic receptor, induced the upregulation of 
Nm23-H1/2 at relatively low concentrations of 0.5 μM 
and increased CREB phosphorylation without altering 
the total amount of CREB (Figure 3B). Although ISO 
treatment at higher concentrations (5, 10 or 50 μM) 
Table 1: Transcription factors associated with G protein signaling that are predicted to be present in the promoter 
regions of NME1 and NME2
TFs 
Relevant 
G protein 
subunits 
No. of predicted TF 
binding sites* Relation to Nm23-H1/2 
expression References 
NME1 NME2
AP-1 G
q
, G
12
5 2 Presence of multiple AP-1 
sites on NME1 promoter
Okada et al., 1996 [12]; Chen et 
al., 1994 [13]; de la Rosa et al., 
1996 [20]
CREB Gs 7 4   
NFAT G
q
, G
βγ
2 3   
NFκB G
i/o
, G
q
1 1 CARMA3 represses NME2 
via NFκB
Chang et al., 2015 [40]
SRE G
12
, G
q
0 2   
STAT Gs, Gq, Gβγ 4 3 Negative feedback between 
STAT3 and Nm23-H1
Gong et al., 2013 [36]
* Numbers of binding sites are predicted by MatInspector.
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Figure 1: RGS19 upregulates the protein level of Nm23-H1/2 and activates the transcription factors AP-1, CRE, 
SRE and STAT3. (A) Locations of G protein signaling-associated transcription factor binding sites on NME1/2 promoter regions were 
predicted by the MatInspector program. TIS, translational initiation site; 5’-UTR, 5’-untranslated region. (B) Lysates of HEK293 and 
293/RGS19 cells were subjected to Western blot for detecting Nm23-H1/2 and HA-RGS19 with anti-Nm23H1/2 and anti-HA antibodies, 
respectively. Representative immunoblots are shown. β-actin was used as an internal control; quantification of mean band intensities by 
Image J is shown on top with the values normalized against the control (parental cell). *RGS19 and Nm23-H1/2 expressions in 293/RGS19 
cells are significantly higher than those of HEK293 cells (P < 0.05). (C) HeLa cells were transiently transfected with cDNAs encoding HA-
RGS19 or vector (pcDNA3.0) and lysates were assayed as in B. (D) Activation of transcriptional factors by transient expression of RGS19 
in HEK293 cells. HEK293 cells were transiently co-transfected with either HA-RGS19 or vector in combination with different luciferase 
reporter genes (at 0.5, 0.75, or 1.0 μg) as indicated. Transfected cells were cultured for 24 h and lysates were subjected to luciferase assay. 
Data shown are relative values of luciferase normalized to the respective vector controls. Each bar represents the average of triplicate 
determinations ± S.E. RLU, relative luciferase unit. *Significantly higher than the vector control (P < 0.05).
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remained effective in activating CREB, induction of 
Nm23-H1/2 became weaker (Figure 3B). In addition, a 
time-course experiment showed that the upregulation of 
Nm23-H1/2 protein in HEK293 cells became detectable 
after 1 h of forskolin treatment, which remained elevated 
up to 36 h before trailing off by 48 h (Figure 3C). CREB 
Ser133 phosphorylation was detected as early as 30 min of 
forskolin treatment, indicating that activation of CREB 
preceded upregulation of Nm23-H1/2 (Figure 3C). CREB 
phosphorylation remained elevated up to 48 h, consistent 
with the Nm23-H1/2 upregulation. In addition, cAMP 
analogues were utilized to investigate their potential 
stimulatory effect on the expression of Nm23-H1/2. 
Dibutyryl cAMP (Bt2cAMP), and Sp-adenosine 
3’,5’-cyclic monophosphorothioate (Sp-cAMP) are 
potent, phosphodiesterase-resistant, membrane-permeable 
activators of PKA that are often used to mimic the effects 
of cAMP. Similar to forskolin and ISO, applications (10 
or 50 μM for 24 h) of either cAMP analogues increased 
the protein expression level of Nm23-H1/2 in HEK293 
cells (Figure 3D). CREB Ser133 phosphorylation was also 
elevated by the cAMP analogues.
Besides the classic PKA/CREB cascade, cAMP also 
targets exchange proteins activated by cAMP (EPAC). To 
investigate possible involvement of EPAC in regulating 
cAMP-induced Nm23-H1/2 expression, HEK293 cells 
were treated with an EPAC-specific activator, 007-AM 
(8-(4-Chlorophenylthio)-2'-O- methyladenosine-3',5'-
cyclic monophosphate acetoxymethyl ester) [27]. As 
compared to the vehicle control, the 007-AM treatment 
had no effect on inducing the expression of Nm23-H1/2 
in concentrations ranging from 0.5 to 50 μM (Figure 
Figure 2: Stable overexpression of RGS19 activates the transcription factors AP-1, CRE, SRE but not STAT3. HEK293 
and 293/RGS19 cells were transfected with the indicated luciferase reporter genes. Transfectants were treated with specific agonists 
targeting different transcription factors: PMA (10 nM, 6 h) for AP-1, forskolin (50 μM, 2 h) for CRE, serum (20%, 6 h) for SRE, and IL-6 
(10 ng/ml, 6 h) for STAT3. For PMA and forskolin, 0.1% DMSO was used as the control (Con). Serum-free medium and ddH2O solvent 
were used as the control (Con) for serum and IL-6 treatment, respectively. Lysates were then subjected to luciferase assays. Data shown are 
relative luciferase units (RLU) normalized to the respective controls (HEK293 with no drug treatment); variations within control groups 
are <10%. Expression of HA-RGS19 was assessed by Western blots. *Significantly higher than the parental HEK293; #Significantly higher 
than vehicle treatment (P < 0.05). Each bar represents the mean ± S.E from three independent sets.
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3E), indicating that EPAC proteins may not play a role 
in regulating Nm23 expression. Collectively, these results 
suggest that an increase in intracellular cAMP level can 
induce the expression of Nm23-H1/2, presumably via the 
PKA/CREB pathway.
Forskolin induces the expression of endogenous 
Nm23-H1/2 in cancer cells
Since induction of Nm23-H1/2 in tumor cells may 
provide a means to suppress metastasis, we examined 
the ability of forskolin to elevate the expression of 
Nm23-H1/2 in several cancer cell lines. They include 
the human metastatic breast cancer MDA-MB-231 and 
MDA-MB-435s cells, lung adenocarcinoma A549 cells, 
and cervical cancer HeLa cells. Endogenous expression 
of Nm23-H1/2 in each of these cell lines was confirmed 
by immunodetection (Supplementary Figure 2A). Time 
course experiments revealed that 5 μM forskolin treatment 
for 1 h or more stimulated the expression of Nm23-H1/2 
in MDA-MB-231 cells (Figure 4A). Forskolin-induced 
CREB Ser133 phosphorylation in these cells was detected 
Figure 3: Activation of PKA pathway upregulates the protein level of Nm23-H1/2. (A) HEK293 cells were serum-starved 
overnight, followed by vehicle or forskolin (0.5, 1, 5, 25, or 50 μM) treatment for 24 h. Cell lysates were immunoblotted for detecting 
Nm23-H1/2, CREB and phosphorylated CREB. (B) HEK293 cells were treated as in A except forskolin was replaced by isoproterenol 
(ISO; 0.5, 1, 5, 10, or 50 μM) for 24 h. (C) HEK293 cells were serum-starved overnight, followed by 1 μM forskolin treatment for different 
periods of time. (D) HEK293 cells were treated as in A except forskolin was replaced by Sp-cAMP (10, 50 μM) or Bt2cAMP (10, 50 μM). 
(E) Same as in A except forskolin was replaced by 007-AM (0.5, 1, 5, 10, or 50 μM). Numerical values shown above the immunoreactive 
bands represent relative intensities of Nm23-H1/2 as a ratio of the basal level (vehicle-treated set as 1.0); variations within control groups 
are <10%. *Forskolin and ISO significantly upregulated the protein level of Nm23-H1/2 as compared to vehicle treatment (P < 0.05). Data 
shown represents the mean ± S.E from three independent sets; two other sets yielded similar results.
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Figure 4: Time-dependent upregulation of Nm23-H1/2 protein expression in various cell lines. MDA-MB-231 (A), MDA-
MB-435s (B), A549 (C) and HeLa (D) cells were serum-starved overnight, followed by 5 μM forskolin treatment for different periods of 
time (0.5, 1, 6, 12, 24, 36, 48 h). Cell lysates were immunoblotted for detecting Nm23-H1/2, CREB and phosphorylated CREB. Numerical 
values shown above the immunoreactive bands represent relative intensities of Nm23-H1/2 as a ratio of the basal level at time 0 (set as 1.0). 
(E) HEK293 cells were pre-treated with 50 μM cycloheximide (CHX) in serum-free medium for 4 h and then treated with or without 5 μM 
forskolin or 10 μM Sp-cAMP overnight. (F) HEK293 cells were pre-treated with inhibitors specific for different signaling intermediates: 
10 μM H-89 (PKA), 10 μM U0126 (ERK), 10 μM SB203580 (p38), 10 μM SP600125 (JNK), 10 μM PP1 (c-Src), 5 μM Stattic (STAT3), 
and 100 nM wortmannin (PI3K) for 4 h, followed with 5 μM forskolin treatment overnight. Cell lysates were subjected to Western blotting. 
*Forskolin significantly upregulated the protein expression of Nm23-H1/2 as compared to the vehicle control (P < 0.05); variations within 
control groups are <5%; ‡Significantly inhibited as compared to forskolin alone (P < 0.05).
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at 30 min and beyond (Figure 4A). Likewise, forskolin 
stimulated the expression of Nm23H1/2 in MDA-MB-
435s, A549 and HeLa cells, with the appearance of 
CREB Ser133 phosphorylation preceding the upregulation 
of Nm23-H1/2 (Figures 4B-4D). In the time-course 
experiments, the peak of Nm23-H1/2 protein expression 
nearly always appeared after the phosphorylation of 
CREB, which suggests that Nm23 protein may begin to 
be expressed sometime after CREB becomes activated. 
Amongst the cell lines examined, the magnitude of 
forskolin-induced Nm23-H1/2 upregulation was weakest 
in HeLa cells. This marginal increase may be attributed 
to relatively low expression of endogenous Nm23-H1/2 
in HeLa cells (Supplementary Figure 2A) which 
required longer exposure time for image development. 
Induction of Nm23 protein expression is probably 
mediated via transcriptional activation because increased 
Nm23-H1 transcript level can be detected by RT-PCR 
(Supplementary Figure 2B). The preceding experiments 
suggest that upregulation of Nm23-H1/2 is likely to occur 
via transcriptional activation, and will therefore require 
protein synthesis. Indeed, in HEK293 cells pretreated 
with cycloheximide (CHX; 50 μM for 4 h) to block 
protein synthesis, neither forskolin nor Sp-cAMP was 
able to elevate Nm23-H1/2 protein levels (Figure 4E). 
CHX, however, did not affect the ability of forskolin or 
Sp-cAMP to stimulate PKA as increased CREB Ser133 
phosphorylation was clearly detected (Figure 4E). These 
results collectively indicated that activation of cAMP/
PKA induced Nm23-H1/2 protein expression in various 
cell types including non-cancer and metastatic cancer cell 
lines via transcriptional regulation.
Apart from CREB, other transcription factors such 
as AP-1, STAT3 and SRE are apparently activated by 
RGS19. A complex mechanism may be involved in the 
upregulation of Nm23 by RGS19. To assess the potential 
involvement of additional intermediates in the forskolin-
induced Nm23 expression, various inhibitors targeting 
different signaling molecules were used to pre-treat 
HEK293 cells prior to the induction of Nm23 expression 
by forskolin. H-89, PP1, U0126 and Stattic pre-treatment 
significantly inhibited the forskolin-induced Nm23 protein 
expression, suggesting the possible involvement of c-Src, 
ERK and STAT3 in cAMP-induced upregulation of 
Nm23, respectively (Figure 4F). In contrast, SB203580, 
SP600125 and wortmannin were unable to block the 
forskolin-induced response, which indicated a lack of 
involvement of p38 MAPK, c-Jun N-terminal kinase, and 
phosphoinositide 3-kinase.
Nm23-H1/2 protein expression is suppressed by 
PKA inhibitor
Nextwe used the PKA-specific inhibitor H-89 to 
test if basal and forskolin-induced Nm23 expression is 
dependent on PKA activity. We first examined the effect 
of H-89 on the expression of endogenous Nm23-H1/2 in 
HeLa cells. As shown in Figure 5A, Nm23-H1/2 levels 
remained relatively stable up to 12 h of H-89 treatment, 
but a significant decrease (>60%) was observed at 24 h of 
treatment. Basal CREB Ser133 phosphorylation was also 
reduced upon H-89 treatment at 24 h. Furthermore, H-89 
pre-treatment blocked the forskolin-induced Nm23-H1/2 
expression or CREB Ser133 phosphorylation (Figure 5B). 
Because Nm23-H1/2 was upregulated in 293/RGS19 cells, 
it would be interesting to investigate whether this could 
be reversed by H-89. Indeed, H-89 treatment significant 
suppressed the expression of Nm23-H1/2 in 293/RGS19 
cells in a time-dependent manner and, likewise, CREB 
Ser133 phosphorylation was reduced by the H-89 (Figure 
5C). Unexpectedly, the level of HA-RGS19 in 293/
RGS19 cells was also attenuated upon H-89 treatment 
in a time-dependent manner, with a reduction of 50% 
by 12 h (Figure 5C). The ability of H-89 to inhibit 
forskolin-induced Nm23-H1/2 upregulation occurred 
in a concentration-dependent manner in both HeLa and 
HEK293 cells (Figure 5D). Moreover, H-89 pretreatment 
similarly inhibited the forskolin response in MDA-MB-
435s metastatic breast cancer cells (Figure 5D). Taken 
together, these results suggest that PKA signaling plays 
an important role in modulating the expression level of 
Nm23-H1/2.
cAMP/PKA activation suppresses metastatic 
cancer cell migration
As a metastasis suppressor, Nm23 is capable of 
inhibiting cell migration [28]. We thus asked whether the 
upregulation of Nm23-H1/2 by cAMP/PKA activation 
would affect the migration of cancer cells. Activation 
of the cAMP/PKA pathway by ISO or Bt2cAMP 
significantly inhibited the migration of A549 cells in the 
transwell migration assay, whereas forskolin elicited a 
weak inhibitory effect (Figure 6A). Also, wound healing 
assay showed that activation of the cAMP/PKA pathway 
significantly suppressed the migration of A549 cells; 
forskolin, ISO and Bt2cAMP treatment significantly 
increased the open space as compared to the control group 
with DMSO treatment (Figure 6B). Since the loss of 
Nm23H1/2 will invariably enhance cell migration [28], a 
knockdown approach would not reveal the involvement 
of Nm23H1/2 downstream of the cAMP/PKA/CREB 
pathway. To test whether elevated levels of Nm23H1/2 
can indeed suppress the mobility of cancer cells, MDA-
MB-231 cells stably expressing Nm23H1 or H2 (MDA/H1 
or MDA/H2) were established. Expression of Nm23H1/2 
was confirmed by Western blot analysis using an anti-
Nm23 antiserum (Figure 6C). In the wound healing assay, 
migration of parental MDA-MB-231 cells gradually 
reduced the open space to less than 40% by 24 h, whereas 
the open space of MDA/H1 and MDA/H2 remained at 
70% or more (Figure 6D). Parental MDA-MB-231 cells 
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treated with forskolin or ISO also left a broader open 
space as compared to the DMSO control group (Figure 
6E). In the transwell migration assay, MDA/H1 and MDA/
H2 cells exhibited reduced mobility (Figure 6F) that 
resembled the impairment induced by ISO and Bt2cAMP 
treatment (Figure 6A). Taken together, these results 
illustrate that the activation of cAMP/PKA suppresses the 
behavior of cancer cell migration.
DISCUSSION
Numerous studies ranging from knockout mice 
experiments to clinical cancer cohort trials have clearly 
demonstrated the multi-functional and metastasis 
suppressive effects of Nm23 [29], thus paving the way 
to develop new anti-metastasis therapies by manipulating 
the expression level of Nm23 [10]. Driven by the recent 
Figure 5: Suppression of Nm23-H1/2 protein level by PKA inhibitor H-89. (A) HeLa cells were incubated with 10 μM 
H-89 or vehicle in serum-free medium for the indicated time. (B) HeLa cells were pretreated with 10 μM H-89 or vehicle in serum-free 
medium overnight, and then incubated with 1 μM forskolin for 24 h. (C) HEK293 or 293/RGS19 cells were serum-starved overnight prior 
to treatment with 10 μM H-89 for the indicated durations. Numerical values shown above the immunoreactive bands represent relative 
intensities of Nm23-H1/2 as a ratio of the control (HEK293 cells with vehicle treatment). (D) HeLa, HEK293, or MDA-MB-435s cells 
were pretreated with 1, 5, 10 μM H-89 or vehicle in serum-free medium for 4 h, and then incubated with 5 μM forskolin overnight without 
removal of the H-89. Values shown above the immunoreactive bands represent relative intensities of Nm23-H1/2 as ratio of the control 
(forskolin alone); variations within control groups are <10%. Cell lysates were immunoblotted for detecting HA-RGS19, Nm23-H1/2, 
CREB and phosphorylated CREB. Immunoblots shown are representatives of three individual sets of experiments. *H-89 significantly 
suppressed the expression level of Nm23-H1/2 as compared to the corresponding controls (time zero or vehicle treatment; P < 0.05).
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observation that RGS19 can upregulate the expression 
of Nm23-H1/2 [15], we have further examined the 
mechanistic basis of this regulation and herein present 
several lines of evidence that implicate the involvement 
of the cAMP/PKA/CREB pathway: (1) Transient or stable 
expression of RGS19 activated the CRE transcription 
element which is present on the promoter regions of 
NME1/2; (2) Manipulation of cAMP/PKA/CREB 
signaling accordingly stimulated or suppressed the 
transcription and expression of Nm23-H1/2; (3) Agonist-
Figure 6: The effect of PKA activation on cancer cell migration. (A) Metastatic lung cancer A549 cells were subjected to the 
following drug treatment for 24 h in serum-free medium: vehicle (DMSO, 0.5% v/v), forskolin (FSK, 5 μM), isoproterenol (ISO, 1 μM), 
and Bt2cAMP (10 μM). After the treatment, cells were reseeded into the inserts of transwell plates and allowed to migrate for 24 h prior to 
fixation and staining. Images were obtained with an Olympus 1X-HOS imaging system at 100× magnification and representative photos 
of each condition are shown. Quantification of the images is shown below the micrographs. (B) Confluent monolayer of A549 cells was 
scratched with a yellow tip and washed with PBS. Cells were allowed to migrate into the open wound for 24 h in the absence or presence 
of PKA activating agents as in panel A. Images were taken immediately after creating the wound and at 24 h. The open space (%) was 
the ratio of wounded area not covered by migratory cells after migration to that of time zero. (C) Metastatic breast cancer MDA-MB-231 
cells stably overexpressing Nm23H1 or Nm23H2 were established as described in Materials and Methods. Cell lysates were analyzed by 
Western blotting with an anti-Nm23H1/2 antiserum. (D) MDA-MB-231 cells overexpressing Nm23H1 or Nm23H2 were subjected to the 
wound healing assay. (E) Parental MDA-MB-231 cells were treated with PKA activators and assayed as in panel B. (F) MDA-MB-231 
cells overexpressing Nm23H1 or Nm23H2 were subjected to transwell migration assay as in panel A. *Significantly different to that of the 
corresponding vehicle or control group (P < 0.05).
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induced stimulation of Gs-coupled receptors resulted in 
the upregulation of Nm23-H1/2; and (4) Activation of 
the cAMP/PKA/CREB pathway suppressed cancer cell 
migration. Moreover, our data further suggests a complex 
regulatory mechanism which may involve other signaling 
intermediates such as c-Src and STAT3.
In this study, we observed an activation of CREB 
by RGS19 as demonstrated by both the pCRE-luc reporter 
assay and the phosphorylation of CREB. The ability of 
RGS19 to stimulate the cAMP/PKA/CREB pathway is 
rather intriguing and may be mediated indirectly because 
RGS19 does not seem to significantly affect the formation 
of cAMP (Supplementary Figure 3). As a GAP for Gα
i/o
 
subunits [21], RGS19 can potentially elevate intracellular 
cAMP by limiting the inhibitory actions of Gαi on AC, 
thereby allowing Gαs to stimulate the production of cAMP 
more efficiently (Figure 7). Although such a mechanism 
is plausible, it would imply that other RGS proteins 
which also serve as GAPs for Gαi may similarly enhance 
cAMP accumulation. Expression of RGS17 has indeed 
been shown to activate the cAMP/PKA/CREB pathway, 
apparently leading to the growth of pancreatic tumors 
[30]. However, expression of RGS2, 7, and 8 failed to 
upregulate Nm23-H1 in HEK293 cells [15], thereby 
suggesting that the GAP function does not appear to play 
an important role in the regulation of Nm23 expression. 
Since suppression of ERK activity is associated with 
elevated Nm23 levels [31], other Gαi-targeting RGS 
proteins including RGS4, 10, and 20 are probably 
incapable of upregulating Nm23 because they had little 
effect on ERK phosphorylation [15]. Taken together, the 
available information tends to suggest that RGS19 may be 
unique within the RGS family for its ability to upregulate 
Nm23-H1/2 in multiple cell types. This postulation, 
however, would require further confirmation of whether 
RGS17 possesses the ability to upregulate Nm23.
Irrespective of the mechanistic linkage to 
RGS19, the present study undoubtedly demonstrated 
that upregulation of Nm23 can be induced by signals 
that stimulate the formation of cAMP. This may have 
Figure 7: Schematic diagram of possible signaling pathways between RGS19, G proteins, cAMP/PKA cascades and 
transcription factors. As a GAP, RGS19 terminates the action of active GTP-bound Gαi, relieves the inhibition of adenylyl cyclase (AC) 
that produce cAMP. Elevation of intracellular cAMP level and the activation of PKA by agonists of Gs-coupled receptors, AC activator 
(forskolin) and cAMP analogues lead to phosphorylation of CREB, thus driving the expression of Nm23-H1/2. Endogenous or forskolin-
induced Nm23-H1/2 protein expression can be suppressed by H-89 which inhibits PKA. Arrow with solid line, activation; blunted arrow, 
inhibition. CRE, cAMP responsive element; CREB, CRE-binding protein; P, phosphate; PKA, cAMP-dependent protein kinase.
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significant therapeutic implications because many Gs-
coupled receptors including those for follicle-stimulating 
hormone, thyroid-stimulating hormone, and luteinizing 
hormone are intricately associated with tumorigenesis in 
a variety of cancers. Analogues of luteinizing hormone-
releasing hormone represent important options for 
endocrine treatment of metastatic breast cancer, and their 
combined use with other drugs such as tamoxifen and 
MPA have produced beneficial outcomes [32]. MPA has 
long been known to elevate Nm23-H1 expression and 
suppress colony formation of MDA-MB-231 and MDA-
MB-435s human breast carcinoma cells in the soft agar 
assay [19]. Our demonstration of a cAMP/PKA/CREB 
driven upregulation of Nm23 is consistent with the 
reported ability of MPA to elevate intracellular cAMP and 
stimulate the PKA pathway in human endometrial stromal 
cells [33]. Disappointingly, a recent phase II clinical trial 
of MPA failed to warrant its use in metastatic breast cancer 
[34]. Since the cAMP/PKA/CREB pathway can exert both 
growth promoting and inhibiting effects on different types 
of tumors [35], activation of this pathway is unlikely to be 
the sole determinant for the upregulation of Nm23.
In silico analysis of NME1/2 promoter regions 
revealed other important transcription factor binding 
sites besides CREB, such as STAT3 and NFκB. The 
potential ability of STAT3 to regulate Nm23 expression 
warrants further discussion. At least two putative STAT3 
binding sites were predicted to be present in the promoter 
region of NME1 (Figure 1A), and elevated STAT3 
activity was detected upon transient overexpression 
of RGS19 (Figure 1D), but not in the 293/RGS19 cells 
(Figure 2). The contradictory effects in transient and 
stable transfectants may be due to a negative feedback 
regulatory mechanism between Nm23 and STAT3. IL-
6-induced STAT3 activation is significantly enhanced 
in A549 cells upon siRNA-mediated knockdown of 
Nm23-H1, an effect which can be prevented by the ectopic 
expression of shRNA-resistant Nm23-H1 [36]. Thus, 
stable expression of RGS19 in 293/RGS19 cells might 
trigger negative feedback regulation on STAT3 because 
of the sustained elevation of Nm23-H1/2. Since Stattic 
effectively inhibited the forskolin-induced upregulation of 
Nm23 in HEK293 cells (Figure 4E), it seems that STAT3 
activation is involved in the transcriptional control of 
Nm23. However, it should also be noted that repression 
of Nm23-H1 by STAT3 has been demonstrated in human 
trophoblasts [37]. The dynamic interactions between 
STAT3 and Nm23 isoforms may provide regulatory 
mechanisms for fine tuning the expression of Nm23, 
STAT3, or both. As forskolin-induced upregulation of 
Nm23 was sensitive to ERK and c-Src inhibition (Figure 
4E), additional regulatory controls might be present along 
the cAMP/PKA/CREB pathway that leads to Nm23 
transcription. Precedent of c-Src enhancing ISO-induced 
cAMP accumulation has indeed been reported in murine 
fibroblasts [38]. Moreover, both ERK and c-Src are known 
to stimulate STAT3 activity [39].
Another recent study suggests that Nm23-H2 
expression is suppressed by NFκB-dependent induction of 
miR-182 [40], which is consistent with the lack of NFκB 
activity in HEK293 cells expressing RGS19 (Figure 1D). 
Interestingly, a splice variant of Nm23-H1, the NME1L, 
can negatively regulate NFκB signaling by interacting 
with IKK [41]. It would appear that the expression of 
Nm23-H1/2 is tightly controlled by complex regulatory 
mechanisms wherein the different Nm23 splice variants 
may play distinct roles. Specific regulation of Nm23 
isoforms may be necessary in view of their differential 
abilities to regulate biochemical and cellular responses 
[42, 43].
The linkage between RGS19, cAMP/CREB 
pathway and Nm23-H1/2 expression described herein 
may provide clues to the in vivo effectiveness of cAMP-
modifying agents that suppress cancer cell migration [44, 
45]. In in vivo experimental models, the PDE inhibitor 
dipyridamole decreases metastasis formation in xenograft 
animals [46], an effect which may well be mediated via 
the upregulation of Nm23-H1/2. More interestingly, it has 
been suggested that PKA participates in the differentiation 
of tumor-initiating cells by enforcing residence in 
the epithelial state and reversing the epithelial-to-
mesenchymal transition program [47]. In carcinoma 
cells, entry into a more mesenchymal state is associated 
with elevated metastatic ability and drug-resistance to 
conventional chemotherapeutics [48]. Similarly, activation 
of β2-adrenergic receptor by the highly-selective (R, R’)-
4’-methoxy-1-naphthylfenoterol [(R, R’)-MNF] inhibits 
proliferation and motility of melanoma cells [49]. This 
effect by (R, R’)-MNF was mimicked by ISO, forskolin, 
and the phosphodiesterase 4 inhibitor Ro 201724 
[49], suggesting a crucial role of cAMP/PKA for this 
phenomenon. However, evidence relating to the cAMP/
PKA pathway and cancer metastatic behavior remains 
somewhat controversial. For instance, β-blockers have 
been shown to exhibit anti-metastatic effects [50]. The 
present results demonstrating that cAMP/PKA/CREB 
activation upregulates metastasis suppressor Nm23-H1/2 
in various cancer cell lines may provide a possible 
mechanism to understand the relationship between the 
cAMP/PKA/CREB pathway and cancer cell metastasis.
MATERIALS AND METHODS
cDNA constructs, cell culture and antibodies
The cDNA of RGS19 was purchased from 
Missouri S&T cDNA Resource Center (Rolla, MO, 
USA). The cDNAs of human Nm23H1 and Nm23H2 
were kindly provided by Dr. Patricia S. Steeg (National 
Cancer Institute) and Dr. Tina H. Lee (Carnegie Mellon 
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University), respectively. Luciferase reporter genes pCRE-
luc, pSRE-luc and pSTAT3-luc were from Clontech 
(Palo Alto, CA), and pAP-1-luc was kindly provided 
by Prof. Karl Tsim (Division of Life Science, Hong 
Kong University of Science and Technology). HEK293, 
MDA-MB-231, MDA-MB-435s, A549, and HeLa cells 
were purchased from and authenticated by the American 
Type Culture Collection (Rockville, MD, USA). Cells 
were cultured in accordance to ATCC recommendations. 
Transfections were performed using LipofectAMINE 
2000 reagent (Life Technologies, Grand Island, NY) 
according to the manufacturer’s protocol. For stable 
transfection in MDA-MB-231 cells, cells were selected by 
0.5 mg/mL G418 for 2-3 weeks. Expression of Nm23H1/2 
was confirmed by immunoblots. Anti-β-actin (A1978) 
was from Sigma-Aldrich, anti-HA (11666606001) from 
Roche, anti-CREB (#9197), anti-phospho-CREB (#9198) 
and anti-Nm23H1/2 (#3338) were from Cell Signaling 
Technology.
In silico sequence analysis
The presence of transcription factor binding sites in 
the putative promoter regions of NME1/2 was predicted 
using the MatInspector version 7.1 [51] at www.genomatix.
de. Sites with scores (core similarity) below 0.75 were not 
considered [52]. The NME1 promoter sequence was from 
GenBank: L35301, L34822; the NME2 promoter sequence 
(2000 bp upstream of 5’ flanking sequence) was from 
Ensemble (NME2 ENSG00000243678). The promoter 
sequences were confirmed with the UCSC genome 
browser at genome.ucsc.edu.
Western blot analysis
After transfection or treatment, cells were 
harvested and lysed in ice-cold lysis buffer containing 
protease inhibitor cocktail. Cell debris was removed by 
centrifugation at 14,000 rpm for 3 min at 4°C, and the 
supernatant was used as total protein lysate. Samples (50 
μg protein) were resolved by 12% or 15% SDS-PAGE 
gel electrophoresis and then transferred to nitrocellulose 
membrane. Target proteins were detected by their specific 
primary antibodies and horseradish peroxidase-conjugated 
secondary antisera. The immunoblots were visualized by 
chemiluminescence with the ECL kit from Amersham. The 
level of β-actin was determined as an internal control.
Luciferase assay
Luciferase assay was performed as described 
previously [53]. The growth medium of serum-starved 
transfectants was removed and cells were lysed with 
lysis buffer provided in the Luciferase Reporter Gene 
Assay High Sensitivity kit (Roche Applied Science). 
The luciferase activity was determined by a microplate 
luminometer LB96V (EG&G Berthold, Germany). Briefly, 
an injector connected to the luciferin substrate was set 
to inject 25 μl of substrate into each well. A period of 1 
second delaying time followed by a 10 sec measuring time 
period was assigned after introduction of subtract. Results 
were collected by WinGlow version 1.24 and expressed as 
relative luminescent units (RLU).
Transwell migration assay
Cells were incubated with compounds of interest 
or vehicle in serum-free medium for overnight and then 
reseeded at 3 × 104 per well in 100 μl medium without 
fetal bovine serum (FBS) in the upper chambers of 24-
well transwell plates (Corning Inc. New York, USA; 8.0 
μm pore size). The lower chambers were loaded with 
600 μl growth medium with 10 % FBS. After incubation 
for 24 h, the inserts were washed with PBS and fixed in 
4% paraformaldehyde for 15 min prior to staining with 
0.5% crystal violet for another 15 min. Cells at the upper 
side of the top chamber were swabbed with cotton strips 
and photos were randomly taken by Olympus 1X-HOS 
imaging system at 100× magnification.
Wound healing assay
Wound healing assay was conducted as previously 
described [54]. Briefly, cancer cells were challenged 
with compounds of interest or vehicle in serum-
free medium for overnight. After washing with PBS, 
confluent monolayers of cells were scratched with yellow 
micropipette tips and cultured in growth medium with 
or without drugs for the indicated periods. Images were 
captured at the onset of the treatment and at selected 
time-points by Olympus 1X-HOS imaging system at 
100× magnification. The open space (%) was calculated 
as a ratio of the wounded area after migration to the 
wounded area before migration. Image J was employed 
to measure the wounded area.
Statistical analysis
Data were expressed as the mean ± S.E. of at least 
three independent sets of experiments. The probability of 
an observed difference being a coincidence was evaluated 
by paired Student’s t test using GraphPad Prism version 
5.01. Differences at values of P < 0.05 were considered 
significant.
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